FI3592355T3 - KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa - Google Patents

KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Info

Publication number
FI3592355T3
FI3592355T3 FIEP18764980.1T FI18764980T FI3592355T3 FI 3592355 T3 FI3592355 T3 FI 3592355T3 FI 18764980 T FI18764980 T FI 18764980T FI 3592355 T3 FI3592355 T3 FI 3592355T3
Authority
FI
Finland
Prior art keywords
day
compound
days
use according
dose
Prior art date
Application number
FIEP18764980.1T
Other languages
English (en)
Finnish (fi)
Inventor
Min-Fun Rudolf Kwan
Johnson Yiu-Nam Lau
E Douglas Kramer
David Lawrence Cutler
Jane Fang
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3592355(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Application granted granted Critical
Publication of FI3592355T3 publication Critical patent/FI3592355T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
FIEP18764980.1T 2017-03-10 2018-03-12 KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa FI3592355T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (1)

Publication Number Publication Date
FI3592355T3 true FI3592355T3 (fi) 2026-02-13

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18764980.1T FI3592355T3 (fi) 2017-03-10 2018-03-12 KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Country Status (22)

Country Link
US (3) US10617693B2 (https=)
EP (2) EP3592355B1 (https=)
JP (3) JP7502863B2 (https=)
KR (2) KR20240090837A (https=)
CN (1) CN110891575A (https=)
AU (2) AU2018231144B2 (https=)
BR (1) BR112019018687A2 (https=)
CA (1) CA3055938A1 (https=)
DK (1) DK3592355T3 (https=)
ES (1) ES3060528T3 (https=)
FI (1) FI3592355T3 (https=)
HR (1) HRP20260155T1 (https=)
IL (1) IL269182B2 (https=)
LT (1) LT3592355T (https=)
MX (2) MX387658B (https=)
NZ (1) NZ757105A (https=)
PL (1) PL3592355T3 (https=)
PT (1) PT3592355T (https=)
RS (1) RS67713B1 (https=)
TW (1) TWI841523B (https=)
WO (1) WO2018165647A1 (https=)
ZA (1) ZA202100106B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
US11752156B2 (en) * 2018-03-07 2023-09-12 Athenex HK Innovative Limited Compositions and methods for treating hyperproliferative skin disorders
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
US20220305021A1 (en) * 2019-06-05 2022-09-29 Athenex, Inc. Methods of treating and/or preventing psoriasis
CA3205857A1 (en) * 2021-01-21 2022-07-28 Michael MOLYNEAUX Compositions and methods for treatment of skin cancers
CN120152984A (zh) * 2023-10-13 2025-06-13 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP2041071B1 (en) 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
US7538252B2 (en) 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
EP2155681B1 (en) 2007-05-17 2018-05-02 Athenex, Inc. Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
WO2010080345A1 (en) * 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
AU2018231144A1 (en) 2019-10-03
US10617693B2 (en) 2020-04-14
MX387658B (es) 2025-03-18
LT3592355T (lt) 2026-02-25
US20230172942A1 (en) 2023-06-08
ES3060528T3 (en) 2026-03-26
JP2020510042A (ja) 2020-04-02
RS67713B1 (sr) 2026-02-27
NZ757105A (en) 2026-02-27
RU2019131757A (ru) 2021-04-12
JP2023015269A (ja) 2023-01-31
AU2018231144B2 (en) 2023-12-21
TW201842913A (zh) 2018-12-16
IL269182B1 (en) 2023-07-01
WO2018165647A1 (en) 2018-09-13
JP7502863B2 (ja) 2024-06-19
PT3592355T (pt) 2026-02-03
EP4659740A2 (en) 2025-12-10
EP3592355A4 (en) 2021-01-06
CA3055938A1 (en) 2018-09-13
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
AU2024201828B2 (en) 2026-02-19
EP3592355A1 (en) 2020-01-15
TWI841523B (zh) 2024-05-11
PL3592355T3 (pl) 2026-04-07
KR20240090837A (ko) 2024-06-21
AU2024201828A1 (en) 2024-05-02
DK3592355T3 (da) 2026-02-16
EP3592355B1 (en) 2025-12-10
HRP20260155T1 (hr) 2026-03-27
MX2019010707A (es) 2020-01-15
KR20190141661A (ko) 2019-12-24
IL269182B2 (en) 2023-11-01
RU2019131757A3 (https=) 2021-05-31
BR112019018687A2 (pt) 2020-04-07
US20180256589A1 (en) 2018-09-13
US11497750B2 (en) 2022-11-15
ZA202100106B (en) 2022-08-31
JP2025029010A (ja) 2025-03-05
EP4659740A3 (en) 2026-02-18
IL269182A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
FI3592355T3 (fi) KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa
SA521421897B1 (ar) تركيبة تعتمد على جزء من نباتات طبية أو مستخلصاتها واستخداماتها ومنتجاتها
JP2016540785A5 (https=)
NO20013859D0 (no) Cyklooksygenase-2 inhibitorpreparater som raskt gir terapeutisk effekt
CO2024012872A2 (es) Tratamiento de neurofibromas plexiformes (pn) asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
JP6400851B2 (ja) ニキビ除去のための医薬組成物とその製造方法
CN110769817A (zh) 皮肤治疗方法、含类视黄醇的组合物及其递送系统
BR112019001948A2 (pt) método de tratamento de um indivíduo humano.
US10071052B2 (en) Method for the prevention and treatment of acne
DK1585513T3 (da) Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi
CN103211982A (zh) 一种治疗三叉神经痛的药物
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
Chowdhury Role of Rohitaka and Sharapunkha on Mukhadushika
PH12022551384A1 (en) Chronic wound healing composition and application thereof
US9757326B2 (en) Hair rejuvenating lotion
EP3348307A1 (en) Composition comprising carnitine, sodium cholate, sodium acetate and optionally silver for use in the treatment of psoriasis, vitiligo e rosacea
MX2025014596A (es) Metodos para tratar la dermatomiositis con brepocitinib
KR20230090185A (ko) 위 점막 병변을 동반한 류마티스 관절염을 치료하는 약제학적 복합제제
KR20220085094A (ko) 알레르기성 결막염을 동반한 만성 비염을 치료하는 약제학적 복합제제
US20190000822A1 (en) Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis
CN104000885B (zh) 一种治疗小儿静脉炎的外敷药物
Ellenberger Do peel-off masks do more harm than good?
RU2021139886A (ru) Способы лечения и/или профилактики псориаза
CN103494940B (zh) 一种治疗酒渣鼻的外用药及其制备方法
MX2025011889A (es) Tratamiento combinado con clascoterona y minoxidil